#United States #Charlotte #financial results #cbdMD #CBD brand

cbdMD Financial Results Overview

cbdMD, Inc. (NYSE American: YCBD), one of the most reputable CBD brands in the U.S., recently reported its preliminary unaudited financial results for the fourth quarter and the entire fiscal year 2025. The company remains a trusted name in the cannabidiol (CBD) market, known for its extensive range of domestically produced CBD products and compliant Delta-9 offerings.

As per the reports, the anticipated net sales revenue for the fiscal year 2025 is projected to range between $19.1 million and $19.3 million. This figure indicates a slight decline from the $19.5 million reported in fiscal 2024. However, the fourth quarter alone shows a promising growth forecast, with net sales expected to be between $4.7 million and $4.9 million, compared to $4.6 million in the same quarter of the previous year. This 3-5% increase reflects the company's ability to maintain a steady sales trajectory despite fluctuations in the wider market.

In terms of profitability, the net loss for fiscal 2025 is expected to show significant improvement, projected between $1.9 million and $2.1 million, down from a net loss of $3.7 million in the previous fiscal year. This positive shift in financial performance underscores the effectiveness of the strategic measures implemented by cbdMD throughout the past year.

The CEO and CFO of cbdMD, Ronan Kennedy, expressed pride in the company's achievements, emphasizing the decisive actions taken to enhance operational efficiency and establish a more robust framework for future growth. He noted, "Our team has worked diligently to sharpen our operating model, which is now yielding tangible results. While many competitors faced significant declines, we have strived to report positive sequential and year-over-year revenue growth."

Kennedy further elaborated on the importance of disciplined cost management and a preoccupation with sustainable profitability. The leadership team at cbdMD is optimistic about the company's trajectory, particularly looking forward to their earnings call scheduled for mid-December. It is also evident that the organization’s years of dedicated effort in improving its business fundamentals are beginning to pay dividends, giving stakeholders confidence in its ongoing ability to navigate complex market dynamics effectively.

cbdMD operates with a broad portfolio of products, including its premium hemp-derived Herbal Oasis brand, which offers THC-infused seltzers aimed at enhancing everyday experiences. Moreover, the company has introduced Paw CBD, a line of veterinarian-formulated pet products, catering to the growing demand for CBD solutions for pets. The recent outreach strategies and product diversifications are also part of a larger vision for sustainable growth, ensuring that cbdMD remains at the forefront of the CBD industry.

Important Notice: It is crucial to mention that the financial results presented are preliminary and unaudited. There's potential for these figures to change as they have yet to undergo an independent audit. Investors should regard this information with the understanding that actual results may vary significantly from these preliminary results.

Conclusion

As the company moves ahead, cbdMD is determined to uphold its reputation as a reliable CBD provider while focusing on strategic improvements and growth. Stakeholders and customers alike can expect ongoing developments that align with cbdMD's commitment to innovation in the CBD sector. Stakeholders can keep informed by checking cbdMD's official site, following the company on social media, or visiting retail locations that stock their products.